Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04610892 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 423
- Enrollment target
NCT04610892: Completed Phase 2 study, sponsored by AstraZeneca.
NCT04610892 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 423 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (218% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04610892, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 423 participants
- Enrollment target
Study Summary
A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
Primary Outcome
To evaluate the effect of MEDI6570 on non-calcified coronary atherosclerotic plaques compared with placebo. The primary endpoint of change in NCPVMD from baseline to Day 253 was assessed based on the CTA Analysis Populations.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MEDI6570
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2023-11-08 |
| Phase | Phase 2 |
What the finished NCT04610892 record still lists
NCT04610892 is an interventional study that assigns participants to a tested intervention. The registered 423 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (218% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04610892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04610892 about?
NCT04610892 is a clinical study titled "Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction". A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
What is the current status of trial NCT04610892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2020-11-04. Estimated completion is 2023-11-08.
What interventions are being tested in trial NCT04610892?
The interventions under investigation include: Placebo (BIOLOGICAL), MEDI6570 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04610892?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04610892's enrollment target sits among peer trials
423 91st of 2000 higher than 1,910 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
- NCT07128628 · 423 participants · Phase 2
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
- NCT05632770 · 424 participants · NA
A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems
- NCT05733767 · 424 participants · Phase 2
Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI